Sibylla technology can be applied to any therapeutic area.Our internal pipeline is currently focused on oncology and antibiotic resistance. The most significant impact on society is for the people suffering from debilitating or even untreatable diseases and their families.

As far as our pipeline is concerned, KRAS mutations are present in 90% of pancreatic cancers, 40% of colorectal cancers, 30% of adenocarcinoma, and other tumors. Nine different KRAS mutations cause over 90% of all KRAS-driven cancers. No therapies have been identified yet for about 85% of these mutations. The societal potential is as huge as a survival hope for millions of patients affected by KRAS-related cancers, specifically those cancers for which there is no cure, e. g. pancreatic cancer. A treatment could be a life-saving option for more than 2.6 M people each year.

CCND1 over-expression due to oncogenic signals promotes transformation to malignant phenotypes. It is amplified in 15% and over-expressed in 30–50% of human breast cancers, in lung, breast, sarcoma, and colon cancer. CCND1 is currently undruggable.

Antibiotic-resistant diseases today kill around 700,000 people each year. A United Nations study says this number could swell to 10 million a year by 2050 if no action is taken. This is more than the number of people who currently die from cancer worldwide every year, and the industry is presently growing in that direction.

The drug discovery industry is heavily involved in the research and experimentation of potential therapies. However, many of them are currently not resolutive and address only part of the cases. We offer an early-stage solution to the development of improved or even life-saving therapies.

Sibylla Biotech S.p.A. services

Services